What is APBD?
Adult polyglucosan body disease (APBD) is a condition that affects the nervous system. People with APBD typically first experience signs and symptoms related to the condition between ages 35 and 60.
How is APBD diagnosed?
How Is APBD Diagnosed? It is diagnosed through evaluation of the symptoms the individual is experiencing, a neurological exam and genetic testing. A skin biopsy can show if the person is making sufficient amounts of functional glycogen branching enzyme. White matter changes will also be visible in an MRI.
What causes APBD?
APBD is caused by mutations in the glycogen branching enzyme gene (GBE1) and is inherited in an autosomal recessive pattern. APBD was first described in the medical literature as a clinical entity in 1980 (Robitaille Y et.
What is Polyglucosan body myopathy?
Polyglucosan body myopathy 1 (PGBM1) is a type of glycogen storage disease that can cause skeletal muscle myopathy and cardiomyopathy with or without immunodeficiency due to a pathogenic mutation in the RBCK1 gene.
What is the most common glycogen storage disease?
Type I (Von Gierke disease) – this is the most common type of glycogen storage disease, and accounts for 90% of all glycogen storage disease cases.
What are two different types of glycogen storage disease?
Types of GSD
- Type I or von Gierke disease. This is the most common form of GSD.
- Type III, Cori disease, or Forbes disease. People with type III don’t have enough of an enzyme called the debranching enzyme, which helps break down glycogen.
- Type IV or Andersen disease. People with type IV form abnormal glycogen.
What enzyme is deficient in glycogen storage disease?
People with type III don’t have enough of an enzyme called the debranching enzyme, which helps break down glycogen. The glycogen can’t fully break down. It collects in the liver and in muscle tissues. Symptoms include a swollen belly, delayed growth, and weak muscles.
What is type 8 glycogen storage disease?
Definition. An x-linked recessive hepatic glycogen storage disease resulting from lack of expression of phosphorylase-b-kinase activity. Symptoms are relatively mild; hepatomegaly, increased liver glycogen, and decreased leukocyte phosphorylase are present. Liver shrinkage occurs in response to glucagon. [